Evidence map›Paper›PMID 32707212›Full record

ArticleDiabetes research and clinical practice2020

Lymphocyte subsets with the lowest decline at baseline and the slow lowest rise during recovery in COVID-19 critical illness patients with diabetes mellitus.

Dafeng Liu, Lijuan Lan, Dongxia Luo, Bennan Zhao, Guo Wei, Yinsheng He, Renqing Zhang, Yaling Liu

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes research and clinical practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
0.2field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Dafeng LiuDepartment of Internal Medicine, The Public and Health Clinic Centre of Chengdu, Chengdu, China. Electronic address: ldf312@126.com.
Lijuan LanDepartment of Internal Medicine, The Public and Health Clinic Centre of Chengdu, Chengdu, China.
Dongxia LuoDepartment of Science and Education, The Public and Health Clinic Centre of Chengdu, Chengdu, China.
Bennan ZhaoDepartment of Internal Medicine, The Public and Health Clinic Centre of Chengdu, Chengdu, China.
Guo WeiDepartment of Surgical Second Ward, The Public and Health Clinic Centre of Chengdu, Chengdu, China.
Yinsheng HeDepartment of Internal Medicine, The Public and Health Clinic Centre of Chengdu, Chengdu, China.
Renqing ZhangDepartment of Vice Headmaster's Office, The Public and Health Clinic Centre of Chengdu, Chengdu, China. Electronic address: cdzrq33@163.com.
Yaling LiuDepartment of Internal Medicine, The Public and Health Clinic Centre of Chengdu, Chengdu, China. Electronic address: cdlyl@sina.com.
Public Health Clinical Center of Chengdu · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHost dysregulation of immune response was highly involved in the pathological process of Coronavirus disease 2019 (COVID-19), especially COVID-19 severe cases with DM.

aimIn this study we aimed at the dynamic change of peripheral lymphocyte and subsets during COVID-19 covery.

methodsThe peripheral lymphocyte and subsets of 95 confirmed cases with COVID-19 from baseline to four weeks were compared between critical illness and non-critical illness cases with or without DM.

resultsThe dynamic characteristics of lymphocyte and subsets in COVID-19 patients was that it reduced significantly at one week, rapidly elevated to the peak at two weeks after onset, then gradually declined during recovery. The COVID-19 critical illness patients with DM had the lowest decline at one week and the slow lowest rise at two weeks after onset, while COVID-19 non-critical illness patients with DM had the rapid highest rise at two weeks after onset, both of them had similar lymphocyte and subsets at five weeks after onset and lower than those patients without DM.

conclusionsThese findings provide a reference for clinicians that for COVID-19 patients with DM and the lowest decline of lymphocyte and subsets, immunomodulatory therapy as soon as possible might avoid or slow down disease progression; moreover for COVID-19 critical illness patients with or without DM and non-critical illness patients with DM, continuous immunomodulatory therapy in later stages of disease might speed up virus clearance, shorten hospital stay, improve disease prognosis in COVID-19 critical illness patients with DM.

Indexed as

B-LymphocytesCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesKiller Cells, NaturalT-Lymphocyte SubsetsAdultAgedAntigens, CD19BetacoronavirusCD3 ComplexCD4 Lymphocyte CountCD56 AntigenComorbidityCoronavirus InfectionsCOVID-19Critical IllnessAntigens, CD19CD3 ComplexCD56 AntigenCoronavirus disease 2019 (COVID-19)Diabetes mellitusDynamic changeLymphocyte subsets

Identifiers

PMID32707212
PMCPMC7373679
OpenAlexW3044273501

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.